Journal
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Volume 35, Issue 1, Pages 107-112Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/147323000703500111
Keywords
advanced glycation end-products (AGEs); nifedipine; diabetic nephropathy; oxidative stress; monocyte chemoattractant protein-1 (MCP-1)
Ask authors/readers for more resources
The interaction between advanced glycation end-products (AGEs) and their receptors mediates the progressive alteration in renal architecture and loss of renal function in diabetic nephropathy. This study investigated whether nifedipine, a widely used anti-hypertensive drug, suppresses expression of monocyte chemoattractant protein-1 (MCP-1), a chemokine that mediates the recruitment of monocytes to inflammatory sites, in AGE-exposed human cultured mesangial cells. Cells were treated with 100 mu g/ml AGE-bovine serum albumin (BSA) or non-glycated BSA in the presence or absence of 1 mu M nifedipine or 50 nM diphenylene iodonium, an inhibitor of reduced nicotinamideadenine dinucleotide phosphate oxidase, for 4 or 24 h. Expression of MCP-1 mRNA was measured using a semi-quantitative reverse transcription-polymerase chain reaction; MCP-1 protein production was measured using an enzyme-linked immunosorbent assay. AGEs significantly increased both MCP-1 mRNA expression and protein production in mesangial cells; this increase was blocked by both nifedipine and diphenylene iodonium. These results suggest that nifedipine could play a protective role against early diabetic nephropathy by suppressing MCP-1 overexpression via blockade of AGE signalling in mesangial cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available